The practical management of testosterone deficiency in men

Abstract

Despite increased global interest in testosterone deficiency in men and its treatment with testosterone therapy, practical aspects of care remain confusing to many practitioners. Testosterone deficiency can result from testicular dysfunction (primary hypogonadism) or hypothalamic–pituitary dysfunction (secondary hypogonadism), and be congenital or acquired. Sexual and nonsexual symptoms of testosterone deficiency can negatively affect quality of life and cause considerable general health concerns. Investigation of testosterone deficiency should be undertaken in men with symptoms of reduced libido, erectile dysfunction, depression, fatigue, poor concentration, and poor memory. Total and free testosterone are the most frequently used tests and evaluating serum concentrations of luteinizing hormone aids determination of primary versus secondary testosterone deficiency. Multiple formulations of testosterone therapy are available, but symptomatic benefits might not manifest for several weeks to many months; long-acting formulations are convenient and improve compliance. Concerns regarding cardiovascular and prostate cancer risks are not supported by current evidence, monitoring during therapy is mandatory. On balance, testosterone therapy can be considered a safe and effective treatment for testosterone deficiency.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Symptoms and signs suggestive of testosterone deficiency in men.

References

  1. 1

    Handelsman, D. J. Global trends in testosterone prescribing, 2000–2011: expanding the spectrum of prescription drug misuse. Med. J. Aust. 199, 548–551 (2013).

    PubMed  Article  PubMed Central  Google Scholar 

  2. 2

    Allan, C. A. & McLachlan, R. I. Androgens and obesity. Curr. Opin. Endocrinol. Diabetes Obes. 17, 224–232 (2010).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  3. 3

    Saad, F., Aversa, A., Isidori, A. M. & Gooren, L. J. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr. Diabetes Rev. 8, 131–143 (2012).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  4. 4

    Saad, F. & Gooren, L. J. The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. J. Obes. http://dx.doi.org/10.1155/2011/471584 (2011).

  5. 5

    Yassin, A. & Doros, G. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clin. Obes. 3, 73–83 (2013).

    PubMed  PubMed Central  Article  Google Scholar 

  6. 6

    Traish, A. M., Guay, A., Feeley, R. & Saad, F. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J. Androl. 30, 10–22 (2009).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  7. 7

    Traish, A. M., Haider, A., Doros, G. & Saad, F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int. J. Clin. Pract. 68, 14–29 (2014).

    Article  CAS  Google Scholar 

  8. 8

    Jones, T. H. et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 34, 828–837 (2011).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  9. 9

    Traish, A. M., Saad, F. & Guay, A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J. Androl. 30, 23–32 (2009).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  10. 10

    Morris, P. D. & Channer, K. S. Testosterone and cardiovascular disease in men. Asian J. Androl. 14, 428–435 (2012).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  11. 11

    Traish, A. M., Saad, F., Feeley, R. J. & Guay, A. The dark side of testosterone deficiency: III. Cardiovascular disease. J. Androl. 30, 477–494 (2009).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  12. 12

    Saad, F. Androgen therapy in men with testosterone deficiency: can testosterone reduce the risk of cardiovascular disease? Diabetes Metab. Res. Rev. 28 (Suppl. 2), 52–59 (2012).

    PubMed  Article  PubMed Central  Google Scholar 

  13. 13

    Yeap, B. B. Androgens and cardiovascular disease. Curr. Opin. Endocrinol. Diabetes Obes. 17, 269–276 (2010).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  14. 14

    Fink, H. A. et al. Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J. Clin. Endocrinol. Metab. 91, 3908–3915 (2006).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  15. 15

    Drummond, E. S., Harvey, A. R. & Martins, R. N. Androgens and Alzheimer's disease. Curr. Opin. Endocrinol. Diabetes Obes. 16, 254–259 (2009).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  16. 16

    Khera, M. Patients with testosterone deficit syndrome and depression. Arch. Esp. Urol. 66, 729–736 (2013).

    PubMed  PubMed Central  Google Scholar 

  17. 17

    Hyde, Z. et al. Low free testosterone predicts frailty in older men: the health in men study. J. Clin. Endocrinol. Metab. 95, 3165–3172 (2010).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  18. 18

    Yeap, B. B. et al. In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. J. Clin. Endocrinol. Metab. 99, E9–E18 (2014).

    PubMed  Article  PubMed Central  Google Scholar 

  19. 19

    Laughlin, G. A., Barrett-Connor, E. & Bergstrom, J. Low serum testosterone and mortality in older men. J. Clin. Endocrinol. Metab. 93, 68–75 (2008).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  20. 20

    Araujo, A. B. et al. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 96, 3007–3019 (2011).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  21. 21

    Menke, A. et al. Sex steroid hormone concentrations and risk of death in US men. Am. J. Epidemiol. 171, 583–592 (2010).

    PubMed  PubMed Central  Article  Google Scholar 

  22. 22

    Malkin, C. J. et al. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 96, 1821–1825 (2010).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  23. 23

    Camacho, E. M. et al. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur. J. Endocrinol. 168, 445–455 (2013).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  24. 24

    Travison, T. G., Araujo, A. B., Kupelian, V., O'Donnell, A. B. & McKinlay, J. B. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J. Clin. Endocrinol. Metab. 92, 549–555 (2007).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  25. 25

    Wu, F. C. et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J. Clin. Endocrinol. Metab. 93, 2737–2745 (2008).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  26. 26

    Bhasin, S. et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 95, 2536–2559 (2010).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  27. 27

    Buvat, J., Maggi, M., Guay, A. & Torres, L. O. Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J. Sex Med. 10, 245–284 (2013).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  28. 28

    Corona, G., Rastrelli, G., Vignozzi, L., Mannucci, E. & Maggi, M. How to recognize late-onset hypogonadism in men with sexual dysfunction. Asian J. Androl. 14, 251–259 (2012).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  29. 29

    Hall, S. A. et al. Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample. J. Clin. Endocrinol. Metab. 93, 3870–3877 (2008).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  30. 30

    Saad, F., Yassin, A., Doros, G., Haider, A. Effects of long-term treatment with testosterone on weight and waist size in 411 hypognadal men with obesity class I-III:observational data from two registry studies. Int. J. Obes. (Lond.) http://dx.doi.org/10.1038/ijo.2015.139.

  31. 31

    Corona, G. et al. Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic. Int. J. Impot. Res. 18, 190–197 (2006).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  32. 32

    Dhindsa, S. et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J. Clin. Endocrinol. Metab. 89, 5462–5468 (2004).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  33. 33

    Grossmann, M. et al. Low testosterone and anaemia in men with type 2 diabetes. Clin. Endocrinol. (Oxf.) 70, 547–553 (2009).

    CAS  Article  Google Scholar 

  34. 34

    Grossmann, M. et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J. Clin. Endocrinol. Metab. 93, 1834–1840 (2008).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  35. 35

    Mulligan, T., Frick, M. F., Zuraw, Q. C., Stemhagen, A. & McWhirter, C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int. J. Clin. Pract. 60, 762–769 (2006).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  36. 36

    Pellitero, S. et al. Hypogonadotropic hypogonadism in morbidly obese males is reversed after bariatric surgery. Obes. Surg. 22, 1835–1842 (2012).

    PubMed  Article  PubMed Central  Google Scholar 

  37. 37

    Schooling, C. M., Au Yeung, S. L., Freeman, G. & Cowling, B. J. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med. 11, 57 (2013).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  38. 38

    Corona, G. et al. The effect of statin therapy on testosterone levels in subjects consulting for erectile dysfunction. J. Sex. Med. 7, 1547–1556 (2010).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  39. 39

    Cohen, P. G. Statins and male hypogonadism. J. Sex. Med. 8, 1826 (2011).

    PubMed  Article  PubMed Central  Google Scholar 

  40. 40

    Reid, I. R., Wattie, D. J., Evans, M. C. & Stapleton, J. P. Testosterone therapy in glucocorticoid-treated men. Arch. Intern. Med. 156, 1173–1177 (1996).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  41. 41

    Crawford, B. A., Liu, P. Y., Kean, M. T., Bleasel, J. F. & Handelsman, D. J. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J. Clin. Endocrinol. Metab. 88, 3167–3176 (2003).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  42. 42

    Brennan, M. J. The effect of opioid therapy on endocrine function. Am. J. Med. 126, S12–S18 (2013).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  43. 43

    Aloisi, A. M. et al. Endocrine consequences of opioid therapy. Psychoneuroendocrinology 34 (Suppl. 1), S162–168 (2009).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  44. 44

    Daniell, H. W. Hypogonadism in men consuming sustained-action oral opioids. J. Pain 3, 377–384 (2002).

    PubMed  Article  PubMed Central  Google Scholar 

  45. 45

    Wu, F. C. et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N. Engl. J. Med. 363, 123–135 (2010).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  46. 46

    Rhoden, E. L. & Morgentaler, A. Risks of testosterone-replacement therapy and recommendations for monitoring. N. Engl. J. Med. 350, 482–492 (2004).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  47. 47

    Saad, F. et al. Effects of testosterone on erectile function: implications for the therapy of erectile dysfunction. BJU Int. 99, 988–992 (2007).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  48. 48

    Bhasin, S. et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 91, 1995–2010 (2006).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  49. 49

    Wang, C. et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J. Androl. 30, 1–9 (2009).

    PubMed  Article  PubMed Central  Google Scholar 

  50. 50

    Dohle, G. R. et al., European Association of Urology guidelines on male hypogonadism, 2014. uroweb.org [online]

  51. 51

    Morgentaler, A., Khera, M., Maggi, M. & Zitzmann, M. Commentary: who is a candidate for testosterone therapy? A synthesis of international expert opinions. J. Sex. Med. 11, 1636–1645 (2014).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  52. 52

    Scovell, J. M., Ramasamy, R., Wilken, N., Kovac, J. R. & Lipshultz, L. I. Hypogonadal symptoms in young men are associated with a serum total testosterone threshold of 400 ng/dL. BJU Int. 116, 142–146 (2015).

    PubMed  Article  PubMed Central  Google Scholar 

  53. 53

    Shea, J. L., Wongt, P. Y. & Chen, Y. Free testosterone: clinical utility and important analytical aspects of measurement. Adv. Clin. Chem. 63, 59–84 (2014).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  54. 54

    Lepage, R. Measurement of testosterone and its sub-fractions in Canada. Clin. Biochem. 39, 97–108 (2006).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  55. 55

    Vermeulen, A., Verdonck, L. & Kaufman, J. M. A critical evaluation of simple methods for the estimation of free testosterone in serum. J. Clin. Endocrinol. Metab. 84, 3666–3672 (1999).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  56. 56

    Gray, A., Feldman, H. A., McKinlay, J. B. & Longcope, C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J. Clin. Endocrinol. Metab. 73, 1016–1025 (1991).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  57. 57

    Paduch, D. A. et al. The laboratory diagnosis of testosterone deficiency. Urology 83, 980–988 (2014).

    PubMed  Article  PubMed Central  Google Scholar 

  58. 58

    Reyes-Vallejo, L., Lazarou, S. & Morgentaler, A. Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone. J. Sex. Med. 4, 1757–1762 (2007).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  59. 59

    Cohen, P. G. The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt--a major factor in the genesis of morbid obesity. Med. Hypotheses 52, 49–51 (1999).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  60. 60

    Fui, M. N., Dupuis, P. & Grossmann, M. Lowered testosterone in male obesity: mechanisms, morbidity and management. Asian J. Androl. 16, 223–231 (2014).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  61. 61

    Winters, S. J., Kelley, D. E. & Goodpaster, B. The analog free testosterone assay: are the results in men clinically useful? Clin. Chem. 44, 2178–2182 (1998).

    CAS  PubMed  PubMed Central  Google Scholar 

  62. 62

    Fritz, K. S., McKean, A. J., Nelson, J. C. & Wilcox, R. B. Analog-based free testosterone test results linked to total testosterone concentrations, not free testosterone concentrations. Clin. Chem. 54, 512–516 (2008).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  63. 63

    Kacker, R., Hornstein, A. & Morgentaler, A. Free testosterone by direct and calculated measurement versus equilibrium dialysis in a clinical population. Aging Male 16, 164–168 (2013).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  64. 64

    Moreno, S. A., Shyam, A. & Morgentaler, A. Comparison of free testosterone results by analog radioimmunoassay and calculated free testosterone in an ambulatory clinical population. J. Sex. Med. 7, 1948–1953 (2010).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  65. 65

    Gupta, S. K., Lindemulder, E. A. & Sathyan, G. Modeling of circadian testosterone in healthy men and hypogonadal men. J. Clin. Pharmacol. 40, 731–738 (2000).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  66. 66

    Winters, S. J. Diurnal rhythm of testosterone and luteinizing hormone in hypogonadal men. J. Androl. 12, 185–190 (1991).

    CAS  PubMed  PubMed Central  Google Scholar 

  67. 67

    Morgentaler, A. Commentary: Guideline for male testosterone therapy: a clinician's perspective. J. Clin. Endocrinol. Metab. 92, 416–417 (2007).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  68. 68

    Bremner, W. J., Vitiello, M. V. & Prinz, P. N. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J. Clin. Endocrinol. Metab. 56, 1278–1281 (1983).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  69. 69

    Brambilla, D. J., Matsumoto, A. M., Araujo, A. B. & McKinlay, J. B. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J. Clin. Endocrinol. Metab. 94, 907–913 (2009).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  70. 70

    Plymate, S. R., Tenover, J. S. & Bremner, W. J. Circadian variation in testosterone, sex hormone-binding globulin, and calculated non-sex hormone-binding globulin bound testosterone in healthy young and elderly men. J. Androl. 10, 366–371 (1989).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  71. 71

    Luboshitzky, R., Shen-Orr, Z. & Herer, P. Middle-aged men secrete less testosterone at night than young healthy men. J. Clin. Endocrinol. Metab. 88, 3160–3166 (2003).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  72. 72

    Collier, C. P. et al. The significance of biological variation in the diagnosis of testosterone deficiency, and consideration of the relevance of total, free and bioavailable testosterone determinations. J. Urol. 183, 2294–2299 (2010).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  73. 73

    Tajar, A. et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J. Clin. Endocrinol. Metab. 95, 1810–1818 (2010).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  74. 74

    Rhoden, E. L., Estrada, C., Levine, L. & Morgentaler, A. The value of pituitary magnetic resonance imaging in men with hypogonadism. J. Urol. 170, 795–798 (2003).

    PubMed  Article  PubMed Central  Google Scholar 

  75. 75

    Finkelstein, J. S. et al. Gonadal steroids and body composition, strength, and sexual function in men. N. Engl. J. Med. 369, 1011–1022 (2013).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  76. 76

    Behre, H. M. & Nieschlag, E. in Testosterone—Action, Deficiency, Substitution 4th edn (eds Nieschlag, E. & Behre, H. M.) 309–335 (2012).

    Google Scholar 

  77. 77

    Giagulli, V. A. et al. Evidence-based medicine update on testosterone replacement therapy (TRT) in male hypogonadism: focus on new formulations. Curr. Pharm. Des. 17, 1500–1511 (2011).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  78. 78

    Schulte-Beerbuhl, M. & Nieschlag, E. Comparison of testosterone, dihydrotestosterone, luteinizing hormone, and follicle-stimulating hormone in serum after injection of testosterone enanthate of testosterone cypionate. Fertil. Steril. 33, 201–203 (1980).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  79. 79

    Minnemann, T. et al. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism. J. Endocrinol. Invest. 31, 718–723 (2008).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  80. 80

    Corona, G., Maseroli, E. & Maggi, M. Injectable testosterone undecanoate for the treatment of hypogonadism. Expert Opin. Pharmacother. 15, 1903–1926 (2014).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  81. 81

    Schubert, M. et al. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J. Clin. Endocrinol. Metab. 89, 5429–5434 (2004).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  82. 82

    Jockenhovel, F. et al. Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men. Eur. J. Endocrinol. 160, 815–819 (2009).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  83. 83

    Jockenhovel, F., Vogel, E., Reinhardt, W. & Reinwein, D. Effects of various modes of androgen substitution therapy on erythropoiesis. Eur. J. Med. Res. 2, 293–298 (1997).

    CAS  PubMed  PubMed Central  Google Scholar 

  84. 84

    Fabbri, A., Giannetta, E., Lenzi, A. & Isidori, A. M. Testosterone treatment to mimic hormone physiology in androgen replacement therapy. A view on testosterone gel and other preparations available. Expert Opin. Biol. Ther. 7, 1093–1106 (2007).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  85. 85

    Abadilla, K. A. & Dobs, A. S. Topical testosterone supplementation for the treatment of male hypogonadism. Drugs 72, 1591–1603 (2012).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  86. 86

    de Ronde, W. Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies. Hum. Reprod. 24, 425–428 (2009).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  87. 87

    Stahlman, J. et al. Serum testosterone levels in non-dosed females after secondary exposure to 1.62% testosterone gel: effects of clothing barrier on testosterone absorption. Curr. Med. Res. Opin. 28, 291–301 (2012).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  88. 88

    Roth, M. Y. & Amory, J. K. Pharmacologic development of male hormonal contraceptive agents. Clin. Pharmacol. Ther. 89, 133–136 (2011).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  89. 89

    Coviello, A. D. et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J. Clin. Endocrinol. Metab. 90, 2595–2602 (2005).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  90. 90

    Saad, F. et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur. J. Endocrinol. 165, 675–685 (2011).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  91. 91

    Morgentaler, A. et al. Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months. J. Sex. Med. 11, 2818–2825 (2014).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  92. 92

    Khera, M. et al. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory. J. Urol. 186, 1005–1011 (2011).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  93. 93

    Morgentaler, A. & Rhoden, E. L. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology 68, 1263–1267 (2006).

    PubMed  Article  PubMed Central  Google Scholar 

  94. 94

    Calof, O. M. et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J. Gerontol. A Biol. Sci. Med. Sci. 60, 1451–1457 (2005).

    PubMed  Article  PubMed Central  Google Scholar 

  95. 95

    Coviello, A. D. et al. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J. Clin. Endocrinol. Metab. 93, 914–919 (2008).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  96. 96

    Lazarou, S., Reyes-Vallejo, L. & Morgentaler, A. Wide variability in laboratory reference values for serum testosterone. J. Sex Med. 3, 1085–1089 (2006).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  97. 97

    Francomano, D., Greco, E. A., Lenzi, A. & Aversa, A. CAG repeat testing of androgen receptor polymorphism: is this necessary for the best clinical management of hypogonadism? J. Sex. Med. 10, 2373–2381 (2013).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  98. 98

    Zitzmann, M. The role of the CAG repeat androgen receptor polymorphism in andrology. Front. Horm. Res. 37, 52–61 (2009).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  99. 99

    Lunenfeld, B. et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male 18, 5–15 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  100. 100

    Lakshman, K. M. et al. The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men. J. Clin. Endocrinol. Metab. 95, 3955–3964 (2010).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  101. 101

    Kacker, R., Traish, A. M. & Morgentaler, A. Estrogens in men: clinical implications for sexual function and the treatment of testosterone deficiency. J. Sex. Med. 9, 1681–1696 (2012).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  102. 102

    Amory, J. K. et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J. Clin. Endocrinol. Metab. 89, 503–510 (2004).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  103. 103

    Tan, R. S., Cook, K. R. & Reilly, W. G. High estrogen in men after injectable testosterone therapy: the low T experience. Am. J. Mens Health 9, 229–234 (2015).

    PubMed  Article  PubMed Central  Google Scholar 

  104. 104

    Vanderschueren, D. et al. Gonadal sex steroid status and bone health in middle-aged and elderly European men. Osteoporos. Int. 21, 1331–1339 (2010).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  105. 105

    Vanderschueren, D. et al. Sex steroid actions in male bone. Endocr. Rev. 35, 906–960 (2014).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  106. 106

    Ohlsson, C., Borjesson, A. E. & Vandenput, L. Sex steroids and bone health in men. Bonekey Rep. 1, 2 (2012).

    PubMed  PubMed Central  Article  Google Scholar 

  107. 107

    Clarke, B. L. & Khosla, S. Androgens and bone. Steroids 74, 296–305 (2009).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  108. 108

    Burnett-Bowie, S. A., McKay, E. A., Lee, H. & Leder, B. Z. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J. Clin. Endocrinol. Metab. 94, 4785–4792 (2009).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  109. 109

    Meriggiola, M. C. et al. Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals. J. Sex. Med. 5, 2442–2453 (2008).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  110. 110

    Yeap, B. B. Sex steroids and cardiovascular disease. Asian J. Androl. 16, 239–247 (2014).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  111. 111

    Vandenplas, G. et al. Endogenous oestradiol and cardiovascular disease in healthy men: a systematic review and meta-analysis of prospective studies. Heart 98, 1478–1482 (2012).

    PubMed  Article  PubMed Central  Google Scholar 

  112. 112

    Rhoden, E. L. & Morgentaler, A. Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole. Int. J. Impot. Res. 16, 95–97 (2004).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  113. 113

    Morgentaler, A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur. Urol. 50, 935–939 (2006).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  114. 114

    Roddam, A. W. et al. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J. Natl Cancer Inst. 100, 170–183 (2008).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  115. 115

    Cui, Y., Zong, H., Yan, H. & Zhang, Y. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 17, 132–143 (2014).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  116. 116

    Wang, C. et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur. Urol. 55, 121–130 (2009).

    PubMed  PubMed Central  Article  Google Scholar 

  117. 117

    Pastuszak, A. W. et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J. Urol. 190, 639–644 (2013).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  118. 118

    Aversa, A., Francomano, D. & Lenzi, A. Cardiometabolic complications after androgen deprivation therapy in a man with prostate cancer: effects of 3 years intermittent testosterone supplementation. Front. Endocrinol. (Lausanne) 3, 17 (2012).

    CAS  Article  Google Scholar 

  119. 119

    Morgentaler, A. et al. Testosterone therapy in men with untreated prostate cancer. J. Urol. 185, 1256–1260 (2011).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  120. 120

    Finkle, W. D. et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS ONE 9, http://dx.doi.org/10.1371/journal.pone.0085805 (2014).

  121. 121

    Vigen, R. et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 310, 1829–1836 (2013).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  122. 122

    Morgentaler, A. et al. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin. Proc. 90, 224–251 (2015).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  123. 123

    Morgentaler, A. Testosterone, cardiovascular risk, and hormonophobia. J. Sex. Med. 11, 1362–1366 (2014).

    PubMed  Article  PubMed Central  Google Scholar 

  124. 124

    Morgentaler, A. Will I have a heart attack or stroke if I take testosterone therapy? J. Sex. Med. 11, 1601–1602 (2014).

    PubMed  Article  PubMed Central  Google Scholar 

  125. 125

    Morgentaler, A. & Kacker, R. Andrology: Testosterone and cardiovascular risk—deciphering the statistics. Nat. Rev. Urol. 11, 131–132 (2014).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  126. 126

    Morgentaler, A. & Lunenfeld, B. Testosterone and cardiovascular risk: world's experts take unprecedented action to correct misinformation. Aging Male 17, 63–65 (2014).

    PubMed  Article  PubMed Central  Google Scholar 

  127. 127

    Page, S. T. Testosterone, cardiovascular disease, and mortality in men: living in the dark. Lancet Diabetes Endocrinol. 2, 609–611 (2014).

    PubMed  Article  PubMed Central  Google Scholar 

  128. 128

    Corona, G. et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin. Drug Saf. 13, 1327–1351 (2014).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  129. 129

    Basaria, S. et al. Adverse events associated with testosterone administration. N. Engl. J. Med. 363, 109–122 (2010).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  130. 130

    Xu, L., Freeman, G., Cowling, B. J. & Schooling, C. M. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 11, 108 (2013).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  131. 131

    Haring, R. et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20–79. Eur. Heart J. 31, 1494–501 (2010).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  132. 132

    Hyde, Z. et al. Low free testosterone predicts mortality from cardiovascular disease but not other causes: the Health in Men Study. J. Clin. Endocrinol. Metab. 97, 179–189 (2012).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  133. 133

    Khaw, K. T. et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 116, 2694–2701 (2007).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  134. 134

    Muraleedharan, V., Marsh, H., Kapoor, D., Channer, K. S. & Jones, T. H. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur. J. Endocrinol. 169, 725–733 (2013).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  135. 135

    Shores, M. M., Matsumoto, A. M., Sloan, K. L. & Kivlahan, D. R. Low serum testosterone and mortality in male veterans. Arch. Intern. Med. 166, 1660–1665 (2006).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  136. 136

    Shores, M. M., Smith, N. L., Forsberg, C. W., Anawalt, B. D. & Matsumoto, A. M. Testosterone treatment and mortality in men with low testosterone levels. J. Clin. Endocrinol. Metab. 97, 2050–2058 (2012).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  137. 137

    Francomano, D., Bruzziches, R., Barbaro, G., Lenzi, A. & Aversa, A. Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study. J. Endocrinol. Invest. 37, 401–411 (2014).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  138. 138

    Aversa, A. et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J. Sex. Med. 7, 3495–3503 (2010).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  139. 139

    Basaria, S. et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. JAMA. 11, 570–581 (2015).

    Article  CAS  Google Scholar 

  140. 140

    English, K. M., Steeds, R. P., Jones, T. H., Diver, M. J. & Channer, K. S. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 102, 1906–1911 (2000).

    CAS  PubMed  Article  Google Scholar 

  141. 141

    Webb, C. M., Adamson, D. L., de Zeigler, D. & Collins, P. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am. J. Cardiol. 83, 437–439, (1999).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  142. 142

    Rosano, G. M. et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 99, 1666–1670 (1999).

    CAS  PubMed  Article  Google Scholar 

  143. 143

    Caminiti, G. et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J. Am. Coll. Cardiol. 54, 919–927 (2009).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  144. 144

    Malkin, C. J. et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur. Heart J. 27, 57–64 (2006).

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  145. 145

    Pugh, P. J., Jones, R. D., West, J. N., Jones, T. H. & Channer, K. S. Testosterone treatment for men with chronic heart failure. Heart 90, 446–447 (2004).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  146. 146

    Francomano, D. et al. Acute endothelial response to testosterone gel administration in men with severe hypogonadism and its relationship to androgen receptor polymorphism: a pilot study. J. Endocrinol. Invest. http://dx.doi.org/10.1007/s40618-015-0325-4.

Download references

Author information

Affiliations

Authors

Contributions

Both authors researched the data for the article, provided substantial contributions to discussion of content, wrote the article, reviewed and edited it before its submission.

Corresponding author

Correspondence to Antonio Aversa.

Ethics declarations

Competing interests

A.A. has received speaker's honoraria from Bayer, Eli-Lilly and Menarini. A.M. has been on the scientific advisory board or worked as a consultant for AbbVie Inc., Auxilium Pharmaceuticals, Inc., Clarus Therapeutics, Endo Pharmaceuticals, and TesoRx, has received research funding from Antares Pharma, Auxilium Pharmaceuticals, Inc., Lipocine Inc. and Eli Lilly and has received lecture honoraria from Bayer and Pfizer, he also owns stock as a cofounder of MHB Labs, LLC

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Aversa, A., Morgentaler, A. The practical management of testosterone deficiency in men. Nat Rev Urol 12, 641–650 (2015). https://doi.org/10.1038/nrurol.2015.238

Download citation

Further reading